January 12, 12:00 PM ET / 9:00 AM PT
Webinar: Details provided upon RSVP approval
Dr. Stephen Harrison is the world’s leading expert on NASH. He is internationally known for studies in hepatitis C and non-alcoholic fatty liver disease with over 200 peer reviewed publications in these fields. Dr. Harrison is currently a Visiting Professor of Hepatology at the Radcliffe Department of Medicine, University of Oxford, serves as the Medical Director for Pinnacle Clinical Research, and the President of Summit Clinical Research.
NASH, a severe form of non-alcoholic fatty liver disease, tends to develop in people who are overweight or obese, have diabetes, high cholesterol, or high triglycerides. NASH can lead to cirrhosis, liver failure, liver cancer, cardiovascular disease, and type 2 diabetes. Fueled by the obesity epidemic, it’s estimated that nearly 27 million Americans are affected by NASH, a number that is expected to increase over time, especially since people can have NASH for years before symptoms occur.
Currently, there are no FDA-approved medications to treat NASH, but Can-Fite BioPharma (NYSE MKT:CANF) is working on that. Their orally-available, small molecule drug, Namodenoson is in Phase II clinical trials and showing great promise in this $35B market.
Please join us January 12 for a Fireside Chat with Dr. Pnina Fishman, CEO of Can-Fite BioPharma, and Dr. Harrison. They will discuss NASH, its implications on public health and the opportunities to both control and treat the disease.
Registration is required, so please click the button below to sign up.
All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.